Global HIV and AIDS Vaccine Market Growth 2026-2032
The global HIV and AIDS Vaccine market size is predicted to grow from US$ million in 2025 to US$ million in 2032; it is expected to grow at a CAGR of %from 2026 to 2032.
United States market for HIV and AIDS Vaccine is estimated to increase from US$ million in 2025 to US$ million by 2032, at a CAGR of % from 2026 through 2032.
China market for HIV and AIDS Vaccine is estimated to increase from US$ million in 2025 to US$ million by 2032, at a CAGR of % from 2026 through 2032.
Europe market for HIV and AIDS Vaccine is estimated to increase from US$ million in 2025 to US$ million by 2032, at a CAGR of % from 2026 through 2032.
Global key HIV and AIDS Vaccine players cover Johnson and Johnson (Janssen), Sanofi-Pasteur, Uvax Bio, AELIX Therapeutics, IAVI, etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2025.
LP Information, Inc. (LPI) ' newest research report, the ?HIV and AIDS Vaccine Industry Forecast? looks at past sales and reviews total world HIV and AIDS Vaccine sales in 2025, providing a comprehensive analysis by region and market sector of projected HIV and AIDS Vaccine sales for 2026 through 2032. With HIV and AIDS Vaccine sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world HIV and AIDS Vaccine industry.
This Insight Report provides a comprehensive analysis of the global HIV and AIDS Vaccine landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on HIV and AIDS Vaccine portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms? unique position in an accelerating global HIV and AIDS Vaccine market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for HIV and AIDS Vaccine and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global HIV and AIDS Vaccine.
This report presents a comprehensive overview, market shares, and growth opportunities of HIV and AIDS Vaccine market by product type, application, key manufacturers and key regions and countries.
Segmentation by Type:
What is the 10-year outlook for the global HIV and AIDS Vaccine market?
What factors are driving HIV and AIDS Vaccine market growth, globally and by region?
Which technologies are poised for the fastest growth by market and region?
How do HIV and AIDS Vaccine market opportunities vary by end market size?
How does HIV and AIDS Vaccine break out by Type, by Application?
United States market for HIV and AIDS Vaccine is estimated to increase from US$ million in 2025 to US$ million by 2032, at a CAGR of % from 2026 through 2032.
China market for HIV and AIDS Vaccine is estimated to increase from US$ million in 2025 to US$ million by 2032, at a CAGR of % from 2026 through 2032.
Europe market for HIV and AIDS Vaccine is estimated to increase from US$ million in 2025 to US$ million by 2032, at a CAGR of % from 2026 through 2032.
Global key HIV and AIDS Vaccine players cover Johnson and Johnson (Janssen), Sanofi-Pasteur, Uvax Bio, AELIX Therapeutics, IAVI, etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2025.
LP Information, Inc. (LPI) ' newest research report, the ?HIV and AIDS Vaccine Industry Forecast? looks at past sales and reviews total world HIV and AIDS Vaccine sales in 2025, providing a comprehensive analysis by region and market sector of projected HIV and AIDS Vaccine sales for 2026 through 2032. With HIV and AIDS Vaccine sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world HIV and AIDS Vaccine industry.
This Insight Report provides a comprehensive analysis of the global HIV and AIDS Vaccine landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on HIV and AIDS Vaccine portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms? unique position in an accelerating global HIV and AIDS Vaccine market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for HIV and AIDS Vaccine and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global HIV and AIDS Vaccine.
This report presents a comprehensive overview, market shares, and growth opportunities of HIV and AIDS Vaccine market by product type, application, key manufacturers and key regions and countries.
Segmentation by Type:
- Preventive Vaccine
- Therapeutic Vaccine
- Viral Vector Vaccines
- Recombinant Protein Vaccines
- Nucleic Acid Vaccines (including mRNA Vaccines)
- Other Vaccines
- Americas
- United States
- Canada
- Mexico
- Brazil
- APAC
- China
- Japan
- Korea
- Southeast Asia
- India
- Australia
- Europe
- Germany
- France
- UK
- Italy
- Russia
- Middle East & Africa
- Egypt
- South Africa
- Israel
- Turkey
- GCC Countries
- Johnson and Johnson (Janssen)
- Sanofi-Pasteur
- Uvax Bio
- AELIX Therapeutics
- IAVI
- HKUMed
What is the 10-year outlook for the global HIV and AIDS Vaccine market?
What factors are driving HIV and AIDS Vaccine market growth, globally and by region?
Which technologies are poised for the fastest growth by market and region?
How do HIV and AIDS Vaccine market opportunities vary by end market size?
How does HIV and AIDS Vaccine break out by Type, by Application?
1 SCOPE OF THE REPORT
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats
2 EXECUTIVE SUMMARY
2.1 World Market Overview
2.1.1 Global HIV and AIDS Vaccine Annual Sales 2021-2032
2.1.2 World Current & Future Analysis for HIV and AIDS Vaccine by Geographic Region, 2021, 2025 & 2032
2.1.3 World Current & Future Analysis for HIV and AIDS Vaccine by Country/Region, 2021, 2025 & 2032
2.2 HIV and AIDS Vaccine Segment by Type
2.2.1 Preventive Vaccine
2.2.2 Therapeutic Vaccine
2.2.3 HIV and AIDS Vaccine Sales by Type
2.2.3.1 Global HIV and AIDS Vaccine Sales Market Share by Type (2021-2026)
2.2.3.2 Global HIV and AIDS Vaccine Revenue and Market Share by Type (2021-2026)
2.2.3.3 Global HIV and AIDS Vaccine Sale Price by Type (2021-2026)
2.3 HIV and AIDS Vaccine Segment by Application
2.3.1 Viral Vector Vaccines
2.3.2 Recombinant Protein Vaccines
2.3.3 Nucleic Acid Vaccines (including mRNA Vaccines)
2.3.4 Other Vaccines
2.3.5 HIV and AIDS Vaccine Sales by Application
2.3.5.1 Global HIV and AIDS Vaccine Sale Market Share by Application (2021-2026)
2.3.5.2 Global HIV and AIDS Vaccine Revenue and Market Share by Application (2021-2026)
2.3.5.3 Global HIV and AIDS Vaccine Sale Price by Application (2021-2026)
3 GLOBAL BY COMPANY
3.1 Global HIV and AIDS Vaccine Breakdown Data by Company
3.1.1 Global HIV and AIDS Vaccine Annual Sales by Company (2021-2026)
3.1.2 Global HIV and AIDS Vaccine Sales Market Share by Company (2021-2026)
3.2 Global HIV and AIDS Vaccine Annual Revenue by Company (2021-2026)
3.2.1 Global HIV and AIDS Vaccine Revenue by Company (2021-2026)
3.2.2 Global HIV and AIDS Vaccine Revenue Market Share by Company (2021-2026)
3.3 Global HIV and AIDS Vaccine Sale Price by Company
3.4 Key Manufacturers HIV and AIDS Vaccine Producing Area Distribution, Sales Area, Product Type
3.4.1 Key Manufacturers HIV and AIDS Vaccine Product Location Distribution
3.4.2 Players HIV and AIDS Vaccine Products Offered
3.5 Market Concentration Rate Analysis
3.5.1 Competition Landscape Analysis
3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2024-2026)
3.6 New Products and Potential Entrants
3.7 Market M&A Activity & Strategy
4 WORLD HISTORIC REVIEW FOR HIV AND AIDS VACCINE BY GEOGRAPHIC REGION
4.1 World Historic HIV and AIDS Vaccine Market Size by Geographic Region (2021-2026)
4.1.1 Global HIV and AIDS Vaccine Annual Sales by Geographic Region (2021-2026)
4.1.2 Global HIV and AIDS Vaccine Annual Revenue by Geographic Region (2021-2026)
4.2 World Historic HIV and AIDS Vaccine Market Size by Country/Region (2021-2026)
4.2.1 Global HIV and AIDS Vaccine Annual Sales by Country/Region (2021-2026)
4.2.2 Global HIV and AIDS Vaccine Annual Revenue by Country/Region (2021-2026)
4.3 Americas HIV and AIDS Vaccine Sales Growth
4.4 APAC HIV and AIDS Vaccine Sales Growth
4.5 Europe HIV and AIDS Vaccine Sales Growth
4.6 Middle East & Africa HIV and AIDS Vaccine Sales Growth
5 AMERICAS
5.1 Americas HIV and AIDS Vaccine Sales by Country
5.1.1 Americas HIV and AIDS Vaccine Sales by Country (2021-2026)
5.1.2 Americas HIV and AIDS Vaccine Revenue by Country (2021-2026)
5.2 Americas HIV and AIDS Vaccine Sales by Type (2021-2026)
5.3 Americas HIV and AIDS Vaccine Sales by Application (2021-2026)
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC HIV and AIDS Vaccine Sales by Region
6.1.1 APAC HIV and AIDS Vaccine Sales by Region (2021-2026)
6.1.2 APAC HIV and AIDS Vaccine Revenue by Region (2021-2026)
6.2 APAC HIV and AIDS Vaccine Sales by Type (2021-2026)
6.3 APAC HIV and AIDS Vaccine Sales by Application (2021-2026)
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
6.10 China Taiwan
7 EUROPE
7.1 Europe HIV and AIDS Vaccine by Country
7.1.1 Europe HIV and AIDS Vaccine Sales by Country (2021-2026)
7.1.2 Europe HIV and AIDS Vaccine Revenue by Country (2021-2026)
7.2 Europe HIV and AIDS Vaccine Sales by Type (2021-2026)
7.3 Europe HIV and AIDS Vaccine Sales by Application (2021-2026)
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 MIDDLE EAST & AFRICA
8.1 Middle East & Africa HIV and AIDS Vaccine by Country
8.1.1 Middle East & Africa HIV and AIDS Vaccine Sales by Country (2021-2026)
8.1.2 Middle East & Africa HIV and AIDS Vaccine Revenue by Country (2021-2026)
8.2 Middle East & Africa HIV and AIDS Vaccine Sales by Type (2021-2026)
8.3 Middle East & Africa HIV and AIDS Vaccine Sales by Application (2021-2026)
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 MARKET DRIVERS, CHALLENGES AND TRENDS
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 MANUFACTURING COST STRUCTURE ANALYSIS
10.1 Raw Material and Suppliers
10.2 Manufacturing Cost Structure Analysis of HIV and AIDS Vaccine
10.3 Manufacturing Process Analysis of HIV and AIDS Vaccine
10.4 Industry Chain Structure of HIV and AIDS Vaccine
11 MARKETING, DISTRIBUTORS AND CUSTOMER
11.1 Sales Channel
11.1.1 Direct Channels
11.1.2 Indirect Channels
11.2 HIV and AIDS Vaccine Distributors
11.3 HIV and AIDS Vaccine Customer
12 WORLD FORECAST REVIEW FOR HIV AND AIDS VACCINE BY GEOGRAPHIC REGION
12.1 Global HIV and AIDS Vaccine Market Size Forecast by Region
12.1.1 Global HIV and AIDS Vaccine Forecast by Region (2027-2032)
12.1.2 Global HIV and AIDS Vaccine Annual Revenue Forecast by Region (2027-2032)
12.2 Americas Forecast by Country (2027-2032)
12.3 APAC Forecast by Region (2027-2032)
12.4 Europe Forecast by Country (2027-2032)
12.5 Middle East & Africa Forecast by Country (2027-2032)
12.6 Global HIV and AIDS Vaccine Forecast by Type (2027-2032)
12.7 Global HIV and AIDS Vaccine Forecast by Application (2027-2032)
13 KEY PLAYERS ANALYSIS
13.1 Johnson and Johnson (Janssen)
13.1.1 Johnson and Johnson (Janssen) Company Information
13.1.2 Johnson and Johnson (Janssen) HIV and AIDS Vaccine Product Portfolios and Specifications
13.1.3 Johnson and Johnson (Janssen) HIV and AIDS Vaccine Sales, Revenue, Price and Gross Margin (2021-2026)
13.1.4 Johnson and Johnson (Janssen) Main Business Overview
13.1.5 Johnson and Johnson (Janssen) Latest Developments
13.2 Sanofi-Pasteur
13.2.1 Sanofi-Pasteur Company Information
13.2.2 Sanofi-Pasteur HIV and AIDS Vaccine Product Portfolios and Specifications
13.2.3 Sanofi-Pasteur HIV and AIDS Vaccine Sales, Revenue, Price and Gross Margin (2021-2026)
13.2.4 Sanofi-Pasteur Main Business Overview
13.2.5 Sanofi-Pasteur Latest Developments
13.3 Uvax Bio
13.3.1 Uvax Bio Company Information
13.3.2 Uvax Bio HIV and AIDS Vaccine Product Portfolios and Specifications
13.3.3 Uvax Bio HIV and AIDS Vaccine Sales, Revenue, Price and Gross Margin (2021-2026)
13.3.4 Uvax Bio Main Business Overview
13.3.5 Uvax Bio Latest Developments
13.4 AELIX Therapeutics
13.4.1 AELIX Therapeutics Company Information
13.4.2 AELIX Therapeutics HIV and AIDS Vaccine Product Portfolios and Specifications
13.4.3 AELIX Therapeutics HIV and AIDS Vaccine Sales, Revenue, Price and Gross Margin (2021-2026)
13.4.4 AELIX Therapeutics Main Business Overview
13.4.5 AELIX Therapeutics Latest Developments
13.5 IAVI
13.5.1 IAVI Company Information
13.5.2 IAVI HIV and AIDS Vaccine Product Portfolios and Specifications
13.5.3 IAVI HIV and AIDS Vaccine Sales, Revenue, Price and Gross Margin (2021-2026)
13.5.4 IAVI Main Business Overview
13.5.5 IAVI Latest Developments
13.6 HKUMed
13.6.1 HKUMed Company Information
13.6.2 HKUMed HIV and AIDS Vaccine Product Portfolios and Specifications
13.6.3 HKUMed HIV and AIDS Vaccine Sales, Revenue, Price and Gross Margin (2021-2026)
13.6.4 HKUMed Main Business Overview
13.6.5 HKUMed Latest Developments
14 RESEARCH FINDINGS AND CONCLUSION
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats
2 EXECUTIVE SUMMARY
2.1 World Market Overview
2.1.1 Global HIV and AIDS Vaccine Annual Sales 2021-2032
2.1.2 World Current & Future Analysis for HIV and AIDS Vaccine by Geographic Region, 2021, 2025 & 2032
2.1.3 World Current & Future Analysis for HIV and AIDS Vaccine by Country/Region, 2021, 2025 & 2032
2.2 HIV and AIDS Vaccine Segment by Type
2.2.1 Preventive Vaccine
2.2.2 Therapeutic Vaccine
2.2.3 HIV and AIDS Vaccine Sales by Type
2.2.3.1 Global HIV and AIDS Vaccine Sales Market Share by Type (2021-2026)
2.2.3.2 Global HIV and AIDS Vaccine Revenue and Market Share by Type (2021-2026)
2.2.3.3 Global HIV and AIDS Vaccine Sale Price by Type (2021-2026)
2.3 HIV and AIDS Vaccine Segment by Application
2.3.1 Viral Vector Vaccines
2.3.2 Recombinant Protein Vaccines
2.3.3 Nucleic Acid Vaccines (including mRNA Vaccines)
2.3.4 Other Vaccines
2.3.5 HIV and AIDS Vaccine Sales by Application
2.3.5.1 Global HIV and AIDS Vaccine Sale Market Share by Application (2021-2026)
2.3.5.2 Global HIV and AIDS Vaccine Revenue and Market Share by Application (2021-2026)
2.3.5.3 Global HIV and AIDS Vaccine Sale Price by Application (2021-2026)
3 GLOBAL BY COMPANY
3.1 Global HIV and AIDS Vaccine Breakdown Data by Company
3.1.1 Global HIV and AIDS Vaccine Annual Sales by Company (2021-2026)
3.1.2 Global HIV and AIDS Vaccine Sales Market Share by Company (2021-2026)
3.2 Global HIV and AIDS Vaccine Annual Revenue by Company (2021-2026)
3.2.1 Global HIV and AIDS Vaccine Revenue by Company (2021-2026)
3.2.2 Global HIV and AIDS Vaccine Revenue Market Share by Company (2021-2026)
3.3 Global HIV and AIDS Vaccine Sale Price by Company
3.4 Key Manufacturers HIV and AIDS Vaccine Producing Area Distribution, Sales Area, Product Type
3.4.1 Key Manufacturers HIV and AIDS Vaccine Product Location Distribution
3.4.2 Players HIV and AIDS Vaccine Products Offered
3.5 Market Concentration Rate Analysis
3.5.1 Competition Landscape Analysis
3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2024-2026)
3.6 New Products and Potential Entrants
3.7 Market M&A Activity & Strategy
4 WORLD HISTORIC REVIEW FOR HIV AND AIDS VACCINE BY GEOGRAPHIC REGION
4.1 World Historic HIV and AIDS Vaccine Market Size by Geographic Region (2021-2026)
4.1.1 Global HIV and AIDS Vaccine Annual Sales by Geographic Region (2021-2026)
4.1.2 Global HIV and AIDS Vaccine Annual Revenue by Geographic Region (2021-2026)
4.2 World Historic HIV and AIDS Vaccine Market Size by Country/Region (2021-2026)
4.2.1 Global HIV and AIDS Vaccine Annual Sales by Country/Region (2021-2026)
4.2.2 Global HIV and AIDS Vaccine Annual Revenue by Country/Region (2021-2026)
4.3 Americas HIV and AIDS Vaccine Sales Growth
4.4 APAC HIV and AIDS Vaccine Sales Growth
4.5 Europe HIV and AIDS Vaccine Sales Growth
4.6 Middle East & Africa HIV and AIDS Vaccine Sales Growth
5 AMERICAS
5.1 Americas HIV and AIDS Vaccine Sales by Country
5.1.1 Americas HIV and AIDS Vaccine Sales by Country (2021-2026)
5.1.2 Americas HIV and AIDS Vaccine Revenue by Country (2021-2026)
5.2 Americas HIV and AIDS Vaccine Sales by Type (2021-2026)
5.3 Americas HIV and AIDS Vaccine Sales by Application (2021-2026)
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC HIV and AIDS Vaccine Sales by Region
6.1.1 APAC HIV and AIDS Vaccine Sales by Region (2021-2026)
6.1.2 APAC HIV and AIDS Vaccine Revenue by Region (2021-2026)
6.2 APAC HIV and AIDS Vaccine Sales by Type (2021-2026)
6.3 APAC HIV and AIDS Vaccine Sales by Application (2021-2026)
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
6.10 China Taiwan
7 EUROPE
7.1 Europe HIV and AIDS Vaccine by Country
7.1.1 Europe HIV and AIDS Vaccine Sales by Country (2021-2026)
7.1.2 Europe HIV and AIDS Vaccine Revenue by Country (2021-2026)
7.2 Europe HIV and AIDS Vaccine Sales by Type (2021-2026)
7.3 Europe HIV and AIDS Vaccine Sales by Application (2021-2026)
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 MIDDLE EAST & AFRICA
8.1 Middle East & Africa HIV and AIDS Vaccine by Country
8.1.1 Middle East & Africa HIV and AIDS Vaccine Sales by Country (2021-2026)
8.1.2 Middle East & Africa HIV and AIDS Vaccine Revenue by Country (2021-2026)
8.2 Middle East & Africa HIV and AIDS Vaccine Sales by Type (2021-2026)
8.3 Middle East & Africa HIV and AIDS Vaccine Sales by Application (2021-2026)
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 MARKET DRIVERS, CHALLENGES AND TRENDS
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 MANUFACTURING COST STRUCTURE ANALYSIS
10.1 Raw Material and Suppliers
10.2 Manufacturing Cost Structure Analysis of HIV and AIDS Vaccine
10.3 Manufacturing Process Analysis of HIV and AIDS Vaccine
10.4 Industry Chain Structure of HIV and AIDS Vaccine
11 MARKETING, DISTRIBUTORS AND CUSTOMER
11.1 Sales Channel
11.1.1 Direct Channels
11.1.2 Indirect Channels
11.2 HIV and AIDS Vaccine Distributors
11.3 HIV and AIDS Vaccine Customer
12 WORLD FORECAST REVIEW FOR HIV AND AIDS VACCINE BY GEOGRAPHIC REGION
12.1 Global HIV and AIDS Vaccine Market Size Forecast by Region
12.1.1 Global HIV and AIDS Vaccine Forecast by Region (2027-2032)
12.1.2 Global HIV and AIDS Vaccine Annual Revenue Forecast by Region (2027-2032)
12.2 Americas Forecast by Country (2027-2032)
12.3 APAC Forecast by Region (2027-2032)
12.4 Europe Forecast by Country (2027-2032)
12.5 Middle East & Africa Forecast by Country (2027-2032)
12.6 Global HIV and AIDS Vaccine Forecast by Type (2027-2032)
12.7 Global HIV and AIDS Vaccine Forecast by Application (2027-2032)
13 KEY PLAYERS ANALYSIS
13.1 Johnson and Johnson (Janssen)
13.1.1 Johnson and Johnson (Janssen) Company Information
13.1.2 Johnson and Johnson (Janssen) HIV and AIDS Vaccine Product Portfolios and Specifications
13.1.3 Johnson and Johnson (Janssen) HIV and AIDS Vaccine Sales, Revenue, Price and Gross Margin (2021-2026)
13.1.4 Johnson and Johnson (Janssen) Main Business Overview
13.1.5 Johnson and Johnson (Janssen) Latest Developments
13.2 Sanofi-Pasteur
13.2.1 Sanofi-Pasteur Company Information
13.2.2 Sanofi-Pasteur HIV and AIDS Vaccine Product Portfolios and Specifications
13.2.3 Sanofi-Pasteur HIV and AIDS Vaccine Sales, Revenue, Price and Gross Margin (2021-2026)
13.2.4 Sanofi-Pasteur Main Business Overview
13.2.5 Sanofi-Pasteur Latest Developments
13.3 Uvax Bio
13.3.1 Uvax Bio Company Information
13.3.2 Uvax Bio HIV and AIDS Vaccine Product Portfolios and Specifications
13.3.3 Uvax Bio HIV and AIDS Vaccine Sales, Revenue, Price and Gross Margin (2021-2026)
13.3.4 Uvax Bio Main Business Overview
13.3.5 Uvax Bio Latest Developments
13.4 AELIX Therapeutics
13.4.1 AELIX Therapeutics Company Information
13.4.2 AELIX Therapeutics HIV and AIDS Vaccine Product Portfolios and Specifications
13.4.3 AELIX Therapeutics HIV and AIDS Vaccine Sales, Revenue, Price and Gross Margin (2021-2026)
13.4.4 AELIX Therapeutics Main Business Overview
13.4.5 AELIX Therapeutics Latest Developments
13.5 IAVI
13.5.1 IAVI Company Information
13.5.2 IAVI HIV and AIDS Vaccine Product Portfolios and Specifications
13.5.3 IAVI HIV and AIDS Vaccine Sales, Revenue, Price and Gross Margin (2021-2026)
13.5.4 IAVI Main Business Overview
13.5.5 IAVI Latest Developments
13.6 HKUMed
13.6.1 HKUMed Company Information
13.6.2 HKUMed HIV and AIDS Vaccine Product Portfolios and Specifications
13.6.3 HKUMed HIV and AIDS Vaccine Sales, Revenue, Price and Gross Margin (2021-2026)
13.6.4 HKUMed Main Business Overview
13.6.5 HKUMed Latest Developments
14 RESEARCH FINDINGS AND CONCLUSION
LIST OF TABLES
Table 1. HIV and AIDS Vaccine Annual Sales CAGR by Geographic Region (2021, 2025 & 2032) & ($ millions)
Table 2. HIV and AIDS Vaccine Annual Sales CAGR by Country/Region (2021, 2025 & 2032) & ($ millions)
Table 3. Major Players of Preventive Vaccine
Table 4. Major Players of Therapeutic Vaccine
Table 5. Global HIV and AIDS Vaccine Sales by Type (2021-2026) & (K Units)
Table 6. Global HIV and AIDS Vaccine Sales Market Share by Type (2021-2026)
Table 7. Global HIV and AIDS Vaccine Revenue by Type (2021-2026) & ($ million)
Table 8. Global HIV and AIDS Vaccine Revenue Market Share by Type (2021-2026)
Table 9. Global HIV and AIDS Vaccine Sale Price by Type (2021-2026) & (US$/Unit)
Table 10. Global HIV and AIDS Vaccine Sale by Application (2021-2026) & (K Units)
Table 11. Global HIV and AIDS Vaccine Sale Market Share by Application (2021-2026)
Table 12. Global HIV and AIDS Vaccine Revenue by Application (2021-2026) & ($ million)
Table 13. Global HIV and AIDS Vaccine Revenue Market Share by Application (2021-2026)
Table 14. Global HIV and AIDS Vaccine Sale Price by Application (2021-2026) & (US$/Unit)
Table 15. Global HIV and AIDS Vaccine Sales by Company (2021-2026) & (K Units)
Table 16. Global HIV and AIDS Vaccine Sales Market Share by Company (2021-2026)
Table 17. Global HIV and AIDS Vaccine Revenue by Company (2021-2026) & ($ millions)
Table 18. Global HIV and AIDS Vaccine Revenue Market Share by Company (2021-2026)
Table 19. Global HIV and AIDS Vaccine Sale Price by Company (2021-2026) & (US$/Unit)
Table 20. Key Manufacturers HIV and AIDS Vaccine Producing Area Distribution and Sales Area
Table 21. Players HIV and AIDS Vaccine Products Offered
Table 22. HIV and AIDS Vaccine Concentration Ratio (CR3, CR5 and CR10) & (2024-2026)
Table 23. New Products and Potential Entrants
Table 24. Market M&A Activity & Strategy
Table 25. Global HIV and AIDS Vaccine Sales by Geographic Region (2021-2026) & (K Units)
Table 26. Global HIV and AIDS Vaccine Sales Market Share Geographic Region (2021-2026)
Table 27. Global HIV and AIDS Vaccine Revenue by Geographic Region (2021-2026) & ($ millions)
Table 28. Global HIV and AIDS Vaccine Revenue Market Share by Geographic Region (2021-2026)
Table 29. Global HIV and AIDS Vaccine Sales by Country/Region (2021-2026) & (K Units)
Table 30. Global HIV and AIDS Vaccine Sales Market Share by Country/Region (2021-2026)
Table 31. Global HIV and AIDS Vaccine Revenue by Country/Region (2021-2026) & ($ millions)
Table 32. Global HIV and AIDS Vaccine Revenue Market Share by Country/Region (2021-2026)
Table 33. Americas HIV and AIDS Vaccine Sales by Country (2021-2026) & (K Units)
Table 34. Americas HIV and AIDS Vaccine Sales Market Share by Country (2021-2026)
Table 35. Americas HIV and AIDS Vaccine Revenue by Country (2021-2026) & ($ millions)
Table 36. Americas HIV and AIDS Vaccine Sales by Type (2021-2026) & (K Units)
Table 37. Americas HIV and AIDS Vaccine Sales by Application (2021-2026) & (K Units)
Table 38. APAC HIV and AIDS Vaccine Sales by Region (2021-2026) & (K Units)
Table 39. APAC HIV and AIDS Vaccine Sales Market Share by Region (2021-2026)
Table 40. APAC HIV and AIDS Vaccine Revenue by Region (2021-2026) & ($ millions)
Table 41. APAC HIV and AIDS Vaccine Sales by Type (2021-2026) & (K Units)
Table 42. APAC HIV and AIDS Vaccine Sales by Application (2021-2026) & (K Units)
Table 43. Europe HIV and AIDS Vaccine Sales by Country (2021-2026) & (K Units)
Table 44. Europe HIV and AIDS Vaccine Revenue by Country (2021-2026) & ($ millions)
Table 45. Europe HIV and AIDS Vaccine Sales by Type (2021-2026) & (K Units)
Table 46. Europe HIV and AIDS Vaccine Sales by Application (2021-2026) & (K Units)
Table 47. Middle East & Africa HIV and AIDS Vaccine Sales by Country (2021-2026) & (K Units)
Table 48. Middle East & Africa HIV and AIDS Vaccine Revenue Market Share by Country (2021-2026)
Table 49. Middle East & Africa HIV and AIDS Vaccine Sales by Type (2021-2026) & (K Units)
Table 50. Middle East & Africa HIV and AIDS Vaccine Sales by Application (2021-2026) & (K Units)
Table 51. Key Market Drivers & Growth Opportunities of HIV and AIDS Vaccine
Table 52. Key Market Challenges & Risks of HIV and AIDS Vaccine
Table 53. Key Industry Trends of HIV and AIDS Vaccine
Table 54. HIV and AIDS Vaccine Raw Material
Table 55. Key Suppliers of Raw Materials
Table 56. HIV and AIDS Vaccine Distributors List
Table 57. HIV and AIDS Vaccine Customer List
Table 58. Global HIV and AIDS Vaccine Sales Forecast by Region (2027-2032) & (K Units)
Table 59. Global HIV and AIDS Vaccine Revenue Forecast by Region (2027-2032) & ($ millions)
Table 60. Americas HIV and AIDS Vaccine Sales Forecast by Country (2027-2032) & (K Units)
Table 61. Americas HIV and AIDS Vaccine Annual Revenue Forecast by Country (2027-2032) & ($ millions)
Table 62. APAC HIV and AIDS Vaccine Sales Forecast by Region (2027-2032) & (K Units)
Table 63. APAC HIV and AIDS Vaccine Annual Revenue Forecast by Region (2027-2032) & ($ millions)
Table 64. Europe HIV and AIDS Vaccine Sales Forecast by Country (2027-2032) & (K Units)
Table 65. Europe HIV and AIDS Vaccine Revenue Forecast by Country (2027-2032) & ($ millions)
Table 66. Middle East & Africa HIV and AIDS Vaccine Sales Forecast by Country (2027-2032) & (K Units)
Table 67. Middle East & Africa HIV and AIDS Vaccine Revenue Forecast by Country (2027-2032) & ($ millions)
Table 68. Global HIV and AIDS Vaccine Sales Forecast by Type (2027-2032) & (K Units)
Table 69. Global HIV and AIDS Vaccine Revenue Forecast by Type (2027-2032) & ($ millions)
Table 70. Global HIV and AIDS Vaccine Sales Forecast by Application (2027-2032) & (K Units)
Table 71. Global HIV and AIDS Vaccine Revenue Forecast by Application (2027-2032) & ($ millions)
Table 72. Johnson and Johnson (Janssen) Basic Information, HIV and AIDS Vaccine Manufacturing Base, Sales Area and Its Competitors
Table 73. Johnson and Johnson (Janssen) HIV and AIDS Vaccine Product Portfolios and Specifications
Table 74. Johnson and Johnson (Janssen) HIV and AIDS Vaccine Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 75. Johnson and Johnson (Janssen) Main Business
Table 76. Johnson and Johnson (Janssen) Latest Developments
Table 77. Sanofi-Pasteur Basic Information, HIV and AIDS Vaccine Manufacturing Base, Sales Area and Its Competitors
Table 78. Sanofi-Pasteur HIV and AIDS Vaccine Product Portfolios and Specifications
Table 79. Sanofi-Pasteur HIV and AIDS Vaccine Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 80. Sanofi-Pasteur Main Business
Table 81. Sanofi-Pasteur Latest Developments
Table 82. Uvax Bio Basic Information, HIV and AIDS Vaccine Manufacturing Base, Sales Area and Its Competitors
Table 83. Uvax Bio HIV and AIDS Vaccine Product Portfolios and Specifications
Table 84. Uvax Bio HIV and AIDS Vaccine Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 85. Uvax Bio Main Business
Table 86. Uvax Bio Latest Developments
Table 87. AELIX Therapeutics Basic Information, HIV and AIDS Vaccine Manufacturing Base, Sales Area and Its Competitors
Table 88. AELIX Therapeutics HIV and AIDS Vaccine Product Portfolios and Specifications
Table 89. AELIX Therapeutics HIV and AIDS Vaccine Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 90. AELIX Therapeutics Main Business
Table 91. AELIX Therapeutics Latest Developments
Table 92. IAVI Basic Information, HIV and AIDS Vaccine Manufacturing Base, Sales Area and Its Competitors
Table 93. IAVI HIV and AIDS Vaccine Product Portfolios and Specifications
Table 94. IAVI HIV and AIDS Vaccine Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 95. IAVI Main Business
Table 96. IAVI Latest Developments
Table 97. HKUMed Basic Information, HIV and AIDS Vaccine Manufacturing Base, Sales Area and Its Competitors
Table 98. HKUMed HIV and AIDS Vaccine Product Portfolios and Specifications
Table 99. HKUMed HIV and AIDS Vaccine Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 100. HKUMed Main Business
Table 101. HKUMed Latest Developments
Table 1. HIV and AIDS Vaccine Annual Sales CAGR by Geographic Region (2021, 2025 & 2032) & ($ millions)
Table 2. HIV and AIDS Vaccine Annual Sales CAGR by Country/Region (2021, 2025 & 2032) & ($ millions)
Table 3. Major Players of Preventive Vaccine
Table 4. Major Players of Therapeutic Vaccine
Table 5. Global HIV and AIDS Vaccine Sales by Type (2021-2026) & (K Units)
Table 6. Global HIV and AIDS Vaccine Sales Market Share by Type (2021-2026)
Table 7. Global HIV and AIDS Vaccine Revenue by Type (2021-2026) & ($ million)
Table 8. Global HIV and AIDS Vaccine Revenue Market Share by Type (2021-2026)
Table 9. Global HIV and AIDS Vaccine Sale Price by Type (2021-2026) & (US$/Unit)
Table 10. Global HIV and AIDS Vaccine Sale by Application (2021-2026) & (K Units)
Table 11. Global HIV and AIDS Vaccine Sale Market Share by Application (2021-2026)
Table 12. Global HIV and AIDS Vaccine Revenue by Application (2021-2026) & ($ million)
Table 13. Global HIV and AIDS Vaccine Revenue Market Share by Application (2021-2026)
Table 14. Global HIV and AIDS Vaccine Sale Price by Application (2021-2026) & (US$/Unit)
Table 15. Global HIV and AIDS Vaccine Sales by Company (2021-2026) & (K Units)
Table 16. Global HIV and AIDS Vaccine Sales Market Share by Company (2021-2026)
Table 17. Global HIV and AIDS Vaccine Revenue by Company (2021-2026) & ($ millions)
Table 18. Global HIV and AIDS Vaccine Revenue Market Share by Company (2021-2026)
Table 19. Global HIV and AIDS Vaccine Sale Price by Company (2021-2026) & (US$/Unit)
Table 20. Key Manufacturers HIV and AIDS Vaccine Producing Area Distribution and Sales Area
Table 21. Players HIV and AIDS Vaccine Products Offered
Table 22. HIV and AIDS Vaccine Concentration Ratio (CR3, CR5 and CR10) & (2024-2026)
Table 23. New Products and Potential Entrants
Table 24. Market M&A Activity & Strategy
Table 25. Global HIV and AIDS Vaccine Sales by Geographic Region (2021-2026) & (K Units)
Table 26. Global HIV and AIDS Vaccine Sales Market Share Geographic Region (2021-2026)
Table 27. Global HIV and AIDS Vaccine Revenue by Geographic Region (2021-2026) & ($ millions)
Table 28. Global HIV and AIDS Vaccine Revenue Market Share by Geographic Region (2021-2026)
Table 29. Global HIV and AIDS Vaccine Sales by Country/Region (2021-2026) & (K Units)
Table 30. Global HIV and AIDS Vaccine Sales Market Share by Country/Region (2021-2026)
Table 31. Global HIV and AIDS Vaccine Revenue by Country/Region (2021-2026) & ($ millions)
Table 32. Global HIV and AIDS Vaccine Revenue Market Share by Country/Region (2021-2026)
Table 33. Americas HIV and AIDS Vaccine Sales by Country (2021-2026) & (K Units)
Table 34. Americas HIV and AIDS Vaccine Sales Market Share by Country (2021-2026)
Table 35. Americas HIV and AIDS Vaccine Revenue by Country (2021-2026) & ($ millions)
Table 36. Americas HIV and AIDS Vaccine Sales by Type (2021-2026) & (K Units)
Table 37. Americas HIV and AIDS Vaccine Sales by Application (2021-2026) & (K Units)
Table 38. APAC HIV and AIDS Vaccine Sales by Region (2021-2026) & (K Units)
Table 39. APAC HIV and AIDS Vaccine Sales Market Share by Region (2021-2026)
Table 40. APAC HIV and AIDS Vaccine Revenue by Region (2021-2026) & ($ millions)
Table 41. APAC HIV and AIDS Vaccine Sales by Type (2021-2026) & (K Units)
Table 42. APAC HIV and AIDS Vaccine Sales by Application (2021-2026) & (K Units)
Table 43. Europe HIV and AIDS Vaccine Sales by Country (2021-2026) & (K Units)
Table 44. Europe HIV and AIDS Vaccine Revenue by Country (2021-2026) & ($ millions)
Table 45. Europe HIV and AIDS Vaccine Sales by Type (2021-2026) & (K Units)
Table 46. Europe HIV and AIDS Vaccine Sales by Application (2021-2026) & (K Units)
Table 47. Middle East & Africa HIV and AIDS Vaccine Sales by Country (2021-2026) & (K Units)
Table 48. Middle East & Africa HIV and AIDS Vaccine Revenue Market Share by Country (2021-2026)
Table 49. Middle East & Africa HIV and AIDS Vaccine Sales by Type (2021-2026) & (K Units)
Table 50. Middle East & Africa HIV and AIDS Vaccine Sales by Application (2021-2026) & (K Units)
Table 51. Key Market Drivers & Growth Opportunities of HIV and AIDS Vaccine
Table 52. Key Market Challenges & Risks of HIV and AIDS Vaccine
Table 53. Key Industry Trends of HIV and AIDS Vaccine
Table 54. HIV and AIDS Vaccine Raw Material
Table 55. Key Suppliers of Raw Materials
Table 56. HIV and AIDS Vaccine Distributors List
Table 57. HIV and AIDS Vaccine Customer List
Table 58. Global HIV and AIDS Vaccine Sales Forecast by Region (2027-2032) & (K Units)
Table 59. Global HIV and AIDS Vaccine Revenue Forecast by Region (2027-2032) & ($ millions)
Table 60. Americas HIV and AIDS Vaccine Sales Forecast by Country (2027-2032) & (K Units)
Table 61. Americas HIV and AIDS Vaccine Annual Revenue Forecast by Country (2027-2032) & ($ millions)
Table 62. APAC HIV and AIDS Vaccine Sales Forecast by Region (2027-2032) & (K Units)
Table 63. APAC HIV and AIDS Vaccine Annual Revenue Forecast by Region (2027-2032) & ($ millions)
Table 64. Europe HIV and AIDS Vaccine Sales Forecast by Country (2027-2032) & (K Units)
Table 65. Europe HIV and AIDS Vaccine Revenue Forecast by Country (2027-2032) & ($ millions)
Table 66. Middle East & Africa HIV and AIDS Vaccine Sales Forecast by Country (2027-2032) & (K Units)
Table 67. Middle East & Africa HIV and AIDS Vaccine Revenue Forecast by Country (2027-2032) & ($ millions)
Table 68. Global HIV and AIDS Vaccine Sales Forecast by Type (2027-2032) & (K Units)
Table 69. Global HIV and AIDS Vaccine Revenue Forecast by Type (2027-2032) & ($ millions)
Table 70. Global HIV and AIDS Vaccine Sales Forecast by Application (2027-2032) & (K Units)
Table 71. Global HIV and AIDS Vaccine Revenue Forecast by Application (2027-2032) & ($ millions)
Table 72. Johnson and Johnson (Janssen) Basic Information, HIV and AIDS Vaccine Manufacturing Base, Sales Area and Its Competitors
Table 73. Johnson and Johnson (Janssen) HIV and AIDS Vaccine Product Portfolios and Specifications
Table 74. Johnson and Johnson (Janssen) HIV and AIDS Vaccine Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 75. Johnson and Johnson (Janssen) Main Business
Table 76. Johnson and Johnson (Janssen) Latest Developments
Table 77. Sanofi-Pasteur Basic Information, HIV and AIDS Vaccine Manufacturing Base, Sales Area and Its Competitors
Table 78. Sanofi-Pasteur HIV and AIDS Vaccine Product Portfolios and Specifications
Table 79. Sanofi-Pasteur HIV and AIDS Vaccine Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 80. Sanofi-Pasteur Main Business
Table 81. Sanofi-Pasteur Latest Developments
Table 82. Uvax Bio Basic Information, HIV and AIDS Vaccine Manufacturing Base, Sales Area and Its Competitors
Table 83. Uvax Bio HIV and AIDS Vaccine Product Portfolios and Specifications
Table 84. Uvax Bio HIV and AIDS Vaccine Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 85. Uvax Bio Main Business
Table 86. Uvax Bio Latest Developments
Table 87. AELIX Therapeutics Basic Information, HIV and AIDS Vaccine Manufacturing Base, Sales Area and Its Competitors
Table 88. AELIX Therapeutics HIV and AIDS Vaccine Product Portfolios and Specifications
Table 89. AELIX Therapeutics HIV and AIDS Vaccine Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 90. AELIX Therapeutics Main Business
Table 91. AELIX Therapeutics Latest Developments
Table 92. IAVI Basic Information, HIV and AIDS Vaccine Manufacturing Base, Sales Area and Its Competitors
Table 93. IAVI HIV and AIDS Vaccine Product Portfolios and Specifications
Table 94. IAVI HIV and AIDS Vaccine Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 95. IAVI Main Business
Table 96. IAVI Latest Developments
Table 97. HKUMed Basic Information, HIV and AIDS Vaccine Manufacturing Base, Sales Area and Its Competitors
Table 98. HKUMed HIV and AIDS Vaccine Product Portfolios and Specifications
Table 99. HKUMed HIV and AIDS Vaccine Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 100. HKUMed Main Business
Table 101. HKUMed Latest Developments
LIST OF FIGURES
Figure 1. Picture of HIV and AIDS Vaccine
Figure 2. HIV and AIDS Vaccine Report Years Considered
Figure 3. Research Objectives
Figure 4. Research Methodology
Figure 5. Research Process and Data Source
Figure 6. Global HIV and AIDS Vaccine Sales Growth Rate 2021-2032 (K Units)
Figure 7. Global HIV and AIDS Vaccine Revenue Growth Rate 2021-2032 ($ millions)
Figure 8. HIV and AIDS Vaccine Sales by Geographic Region (2021, 2025 & 2032) & ($ millions)
Figure 9. HIV and AIDS Vaccine Sales Market Share by Country/Region (2025)
Figure 10. HIV and AIDS Vaccine Sales Market Share by Country/Region (2021, 2025 & 2032)
Figure 11. Product Picture of Preventive Vaccine
Figure 12. Product Picture of Therapeutic Vaccine
Figure 13. Global HIV and AIDS Vaccine Sales Market Share by Type in 2026
Figure 14. Global HIV and AIDS Vaccine Revenue Market Share by Type (2021-2026)
Figure 15. HIV and AIDS Vaccine Consumed in Viral Vector Vaccines
Figure 16. Global HIV and AIDS Vaccine Market: Viral Vector Vaccines (2021-2026) & (K Units)
Figure 17. HIV and AIDS Vaccine Consumed in Recombinant Protein Vaccines
Figure 18. Global HIV and AIDS Vaccine Market: Recombinant Protein Vaccines (2021-2026) & (K Units)
Figure 19. HIV and AIDS Vaccine Consumed in Nucleic Acid Vaccines (including mRNA Vaccines)
Figure 20. Global HIV and AIDS Vaccine Market: Nucleic Acid Vaccines (including mRNA Vaccines) (2021-2026) & (K Units)
Figure 21. HIV and AIDS Vaccine Consumed in Other Vaccines
Figure 22. Global HIV and AIDS Vaccine Market: Other Vaccines (2021-2026) & (K Units)
Figure 23. Global HIV and AIDS Vaccine Sale Market Share by Application (2025)
Figure 24. Global HIV and AIDS Vaccine Revenue Market Share by Application in 2026
Figure 25. HIV and AIDS Vaccine Sales by Company in 2026 (K Units)
Figure 26. Global HIV and AIDS Vaccine Sales Market Share by Company in 2026
Figure 27. HIV and AIDS Vaccine Revenue by Company in 2026 ($ millions)
Figure 28. Global HIV and AIDS Vaccine Revenue Market Share by Company in 2026
Figure 29. Global HIV and AIDS Vaccine Sales Market Share by Geographic Region (2021-2026)
Figure 30. Global HIV and AIDS Vaccine Revenue Market Share by Geographic Region in 2026
Figure 31. Americas HIV and AIDS Vaccine Sales 2021-2026 (K Units)
Figure 32. Americas HIV and AIDS Vaccine Revenue 2021-2026 ($ millions)
Figure 33. APAC HIV and AIDS Vaccine Sales 2021-2026 (K Units)
Figure 34. APAC HIV and AIDS Vaccine Revenue 2021-2026 ($ millions)
Figure 35. Europe HIV and AIDS Vaccine Sales 2021-2026 (K Units)
Figure 36. Europe HIV and AIDS Vaccine Revenue 2021-2026 ($ millions)
Figure 37. Middle East & Africa HIV and AIDS Vaccine Sales 2021-2026 (K Units)
Figure 38. Middle East & Africa HIV and AIDS Vaccine Revenue 2021-2026 ($ millions)
Figure 39. Americas HIV and AIDS Vaccine Sales Market Share by Country in 2026
Figure 40. Americas HIV and AIDS Vaccine Revenue Market Share by Country (2021-2026)
Figure 41. Americas HIV and AIDS Vaccine Sales Market Share by Type (2021-2026)
Figure 42. Americas HIV and AIDS Vaccine Sales Market Share by Application (2021-2026)
Figure 43. United States HIV and AIDS Vaccine Revenue Growth 2021-2026 ($ millions)
Figure 44. Canada HIV and AIDS Vaccine Revenue Growth 2021-2026 ($ millions)
Figure 45. Mexico HIV and AIDS Vaccine Revenue Growth 2021-2026 ($ millions)
Figure 46. Brazil HIV and AIDS Vaccine Revenue Growth 2021-2026 ($ millions)
Figure 47. APAC HIV and AIDS Vaccine Sales Market Share by Region in 2026
Figure 48. APAC HIV and AIDS Vaccine Revenue Market Share by Region (2021-2026)
Figure 49. APAC HIV and AIDS Vaccine Sales Market Share by Type (2021-2026)
Figure 50. APAC HIV and AIDS Vaccine Sales Market Share by Application (2021-2026)
Figure 51. China HIV and AIDS Vaccine Revenue Growth 2021-2026 ($ millions)
Figure 52. Japan HIV and AIDS Vaccine Revenue Growth 2021-2026 ($ millions)
Figure 53. South Korea HIV and AIDS Vaccine Revenue Growth 2021-2026 ($ millions)
Figure 54. Southeast Asia HIV and AIDS Vaccine Revenue Growth 2021-2026 ($ millions)
Figure 55. India HIV and AIDS Vaccine Revenue Growth 2021-2026 ($ millions)
Figure 56. Australia HIV and AIDS Vaccine Revenue Growth 2021-2026 ($ millions)
Figure 57. China Taiwan HIV and AIDS Vaccine Revenue Growth 2021-2026 ($ millions)
Figure 58. Europe HIV and AIDS Vaccine Sales Market Share by Country in 2026
Figure 59. Europe HIV and AIDS Vaccine Revenue Market Share by Country (2021-2026)
Figure 60. Europe HIV and AIDS Vaccine Sales Market Share by Type (2021-2026)
Figure 61. Europe HIV and AIDS Vaccine Sales Market Share by Application (2021-2026)
Figure 62. Germany HIV and AIDS Vaccine Revenue Growth 2021-2026 ($ millions)
Figure 63. France HIV and AIDS Vaccine Revenue Growth 2021-2026 ($ millions)
Figure 64. UK HIV and AIDS Vaccine Revenue Growth 2021-2026 ($ millions)
Figure 65. Italy HIV and AIDS Vaccine Revenue Growth 2021-2026 ($ millions)
Figure 66. Russia HIV and AIDS Vaccine Revenue Growth 2021-2026 ($ millions)
Figure 67. Middle East & Africa HIV and AIDS Vaccine Sales Market Share by Country (2021-2026)
Figure 68. Middle East & Africa HIV and AIDS Vaccine Sales Market Share by Type (2021-2026)
Figure 69. Middle East & Africa HIV and AIDS Vaccine Sales Market Share by Application (2021-2026)
Figure 70. Egypt HIV and AIDS Vaccine Revenue Growth 2021-2026 ($ millions)
Figure 71. South Africa HIV and AIDS Vaccine Revenue Growth 2021-2026 ($ millions)
Figure 72. Israel HIV and AIDS Vaccine Revenue Growth 2021-2026 ($ millions)
Figure 73. Turkey HIV and AIDS Vaccine Revenue Growth 2021-2026 ($ millions)
Figure 74. GCC Countries HIV and AIDS Vaccine Revenue Growth 2021-2026 ($ millions)
Figure 75. Manufacturing Cost Structure Analysis of HIV and AIDS Vaccine in 2026
Figure 76. Manufacturing Process Analysis of HIV and AIDS Vaccine
Figure 77. Industry Chain Structure of HIV and AIDS Vaccine
Figure 78. Channels of Distribution
Figure 79. Global HIV and AIDS Vaccine Sales Market Forecast by Region (2027-2032)
Figure 80. Global HIV and AIDS Vaccine Revenue Market Share Forecast by Region (2027-2032)
Figure 81. Global HIV and AIDS Vaccine Sales Market Share Forecast by Type (2027-2032)
Figure 82. Global HIV and AIDS Vaccine Revenue Market Share Forecast by Type (2027-2032)
Figure 83. Global HIV and AIDS Vaccine Sales Market Share Forecast by Application (2027-2032)
Figure 84. Global HIV and AIDS Vaccine Revenue Market Share Forecast by Application (2027-2032)
Figure 1. Picture of HIV and AIDS Vaccine
Figure 2. HIV and AIDS Vaccine Report Years Considered
Figure 3. Research Objectives
Figure 4. Research Methodology
Figure 5. Research Process and Data Source
Figure 6. Global HIV and AIDS Vaccine Sales Growth Rate 2021-2032 (K Units)
Figure 7. Global HIV and AIDS Vaccine Revenue Growth Rate 2021-2032 ($ millions)
Figure 8. HIV and AIDS Vaccine Sales by Geographic Region (2021, 2025 & 2032) & ($ millions)
Figure 9. HIV and AIDS Vaccine Sales Market Share by Country/Region (2025)
Figure 10. HIV and AIDS Vaccine Sales Market Share by Country/Region (2021, 2025 & 2032)
Figure 11. Product Picture of Preventive Vaccine
Figure 12. Product Picture of Therapeutic Vaccine
Figure 13. Global HIV and AIDS Vaccine Sales Market Share by Type in 2026
Figure 14. Global HIV and AIDS Vaccine Revenue Market Share by Type (2021-2026)
Figure 15. HIV and AIDS Vaccine Consumed in Viral Vector Vaccines
Figure 16. Global HIV and AIDS Vaccine Market: Viral Vector Vaccines (2021-2026) & (K Units)
Figure 17. HIV and AIDS Vaccine Consumed in Recombinant Protein Vaccines
Figure 18. Global HIV and AIDS Vaccine Market: Recombinant Protein Vaccines (2021-2026) & (K Units)
Figure 19. HIV and AIDS Vaccine Consumed in Nucleic Acid Vaccines (including mRNA Vaccines)
Figure 20. Global HIV and AIDS Vaccine Market: Nucleic Acid Vaccines (including mRNA Vaccines) (2021-2026) & (K Units)
Figure 21. HIV and AIDS Vaccine Consumed in Other Vaccines
Figure 22. Global HIV and AIDS Vaccine Market: Other Vaccines (2021-2026) & (K Units)
Figure 23. Global HIV and AIDS Vaccine Sale Market Share by Application (2025)
Figure 24. Global HIV and AIDS Vaccine Revenue Market Share by Application in 2026
Figure 25. HIV and AIDS Vaccine Sales by Company in 2026 (K Units)
Figure 26. Global HIV and AIDS Vaccine Sales Market Share by Company in 2026
Figure 27. HIV and AIDS Vaccine Revenue by Company in 2026 ($ millions)
Figure 28. Global HIV and AIDS Vaccine Revenue Market Share by Company in 2026
Figure 29. Global HIV and AIDS Vaccine Sales Market Share by Geographic Region (2021-2026)
Figure 30. Global HIV and AIDS Vaccine Revenue Market Share by Geographic Region in 2026
Figure 31. Americas HIV and AIDS Vaccine Sales 2021-2026 (K Units)
Figure 32. Americas HIV and AIDS Vaccine Revenue 2021-2026 ($ millions)
Figure 33. APAC HIV and AIDS Vaccine Sales 2021-2026 (K Units)
Figure 34. APAC HIV and AIDS Vaccine Revenue 2021-2026 ($ millions)
Figure 35. Europe HIV and AIDS Vaccine Sales 2021-2026 (K Units)
Figure 36. Europe HIV and AIDS Vaccine Revenue 2021-2026 ($ millions)
Figure 37. Middle East & Africa HIV and AIDS Vaccine Sales 2021-2026 (K Units)
Figure 38. Middle East & Africa HIV and AIDS Vaccine Revenue 2021-2026 ($ millions)
Figure 39. Americas HIV and AIDS Vaccine Sales Market Share by Country in 2026
Figure 40. Americas HIV and AIDS Vaccine Revenue Market Share by Country (2021-2026)
Figure 41. Americas HIV and AIDS Vaccine Sales Market Share by Type (2021-2026)
Figure 42. Americas HIV and AIDS Vaccine Sales Market Share by Application (2021-2026)
Figure 43. United States HIV and AIDS Vaccine Revenue Growth 2021-2026 ($ millions)
Figure 44. Canada HIV and AIDS Vaccine Revenue Growth 2021-2026 ($ millions)
Figure 45. Mexico HIV and AIDS Vaccine Revenue Growth 2021-2026 ($ millions)
Figure 46. Brazil HIV and AIDS Vaccine Revenue Growth 2021-2026 ($ millions)
Figure 47. APAC HIV and AIDS Vaccine Sales Market Share by Region in 2026
Figure 48. APAC HIV and AIDS Vaccine Revenue Market Share by Region (2021-2026)
Figure 49. APAC HIV and AIDS Vaccine Sales Market Share by Type (2021-2026)
Figure 50. APAC HIV and AIDS Vaccine Sales Market Share by Application (2021-2026)
Figure 51. China HIV and AIDS Vaccine Revenue Growth 2021-2026 ($ millions)
Figure 52. Japan HIV and AIDS Vaccine Revenue Growth 2021-2026 ($ millions)
Figure 53. South Korea HIV and AIDS Vaccine Revenue Growth 2021-2026 ($ millions)
Figure 54. Southeast Asia HIV and AIDS Vaccine Revenue Growth 2021-2026 ($ millions)
Figure 55. India HIV and AIDS Vaccine Revenue Growth 2021-2026 ($ millions)
Figure 56. Australia HIV and AIDS Vaccine Revenue Growth 2021-2026 ($ millions)
Figure 57. China Taiwan HIV and AIDS Vaccine Revenue Growth 2021-2026 ($ millions)
Figure 58. Europe HIV and AIDS Vaccine Sales Market Share by Country in 2026
Figure 59. Europe HIV and AIDS Vaccine Revenue Market Share by Country (2021-2026)
Figure 60. Europe HIV and AIDS Vaccine Sales Market Share by Type (2021-2026)
Figure 61. Europe HIV and AIDS Vaccine Sales Market Share by Application (2021-2026)
Figure 62. Germany HIV and AIDS Vaccine Revenue Growth 2021-2026 ($ millions)
Figure 63. France HIV and AIDS Vaccine Revenue Growth 2021-2026 ($ millions)
Figure 64. UK HIV and AIDS Vaccine Revenue Growth 2021-2026 ($ millions)
Figure 65. Italy HIV and AIDS Vaccine Revenue Growth 2021-2026 ($ millions)
Figure 66. Russia HIV and AIDS Vaccine Revenue Growth 2021-2026 ($ millions)
Figure 67. Middle East & Africa HIV and AIDS Vaccine Sales Market Share by Country (2021-2026)
Figure 68. Middle East & Africa HIV and AIDS Vaccine Sales Market Share by Type (2021-2026)
Figure 69. Middle East & Africa HIV and AIDS Vaccine Sales Market Share by Application (2021-2026)
Figure 70. Egypt HIV and AIDS Vaccine Revenue Growth 2021-2026 ($ millions)
Figure 71. South Africa HIV and AIDS Vaccine Revenue Growth 2021-2026 ($ millions)
Figure 72. Israel HIV and AIDS Vaccine Revenue Growth 2021-2026 ($ millions)
Figure 73. Turkey HIV and AIDS Vaccine Revenue Growth 2021-2026 ($ millions)
Figure 74. GCC Countries HIV and AIDS Vaccine Revenue Growth 2021-2026 ($ millions)
Figure 75. Manufacturing Cost Structure Analysis of HIV and AIDS Vaccine in 2026
Figure 76. Manufacturing Process Analysis of HIV and AIDS Vaccine
Figure 77. Industry Chain Structure of HIV and AIDS Vaccine
Figure 78. Channels of Distribution
Figure 79. Global HIV and AIDS Vaccine Sales Market Forecast by Region (2027-2032)
Figure 80. Global HIV and AIDS Vaccine Revenue Market Share Forecast by Region (2027-2032)
Figure 81. Global HIV and AIDS Vaccine Sales Market Share Forecast by Type (2027-2032)
Figure 82. Global HIV and AIDS Vaccine Revenue Market Share Forecast by Type (2027-2032)
Figure 83. Global HIV and AIDS Vaccine Sales Market Share Forecast by Application (2027-2032)
Figure 84. Global HIV and AIDS Vaccine Revenue Market Share Forecast by Application (2027-2032)
